The generics only came out last year; the two companies in question had patents that expired last year. This is why everything is going mad; the companies are trying to buy in to the formularies while being aware that if they don’t close the deal PDQ they will not be able to do anything. The generics are made by the same companies. The other manufacturers haven’t had time to build the manufacturing capabilities and they are unwilling to do so because they suspect that the two companies in question will deliberately undercut them for a couple of years to stop them; to put them out of business.
Ademlog is Humalog; it is manufactured by the other company and is chemically identical. It just has another name on the packet.
Just to be absolutely clear because it is very confusing; humalog and novolog seem (from comments on this list) to be pretty much identical, but humalog is the chemical “lispro” and novolog is the chemical “aspart”. The logical approach is for us to ask our doctors to write a prescription for “generic insulin {lispro,aspart}” as appropriate. They are both generics; for an insurance company to deny us a generic then insist we buy an identical tier 2 or 3 drug would be, well, interesting.
Fiasp is, I believe, still covered by a patent, so it works under the old rules. I think this is why the company which owns the patent is pushing it so strongly; it’s just aspart with an accelerant to stimulate the skin and thereby increase the adsorption rate. If your insurance company refuses to approve aspart then getting a prescription for Fiasp is the alternative to using lispro.
As a community I think we need to simply stop using the brand names. My hoover is a dyson, lets not repeat that naming error again.
We should only talk about lispro and aspart.
